Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

por Packer, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A., Pollock, Pamela M.
Publicado 2019

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

por Marusiak, Anna A., Edwards, Zoe C., Hugo, Willy, Trotter, Eleanor W., Girotti, Maria R., Stephenson, Natalie L., Kong, Xiangju, Gartside, Michael G., Fawdar, Shameem, Hudson, Andrew, Breitwieser, Wolfgang, Hayward, Nicholas K., Marais, Richard, Lo, Roger S., Brognard, John
Publicado 2014

Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing

por Stark, Mitchell S, Woods, Susan L, Gartside, Michael G, Bonazzi, Vanessa F, Dutton-Regester, Ken, Aoude, Lauren G, Chow, Donald, Sereduk, Chris, Niemi, Natalie M, Tang, Nanyun, Ellis, Jonathan J, Reid, Jeffrey, Zismann, Victoria, Tyagi, Sonika, Muzny, Donna, Newsham, Irene, Wu, YuanQing, Palmer, Jane M, Pollak, Thomas, Youngkin, David, Brooks, Bradford R, Lanagan, Catherine, Schmidt, Christopher W, Kobe, Bostjan, MacKeigan, Jeffrey P, Yin, Hongwei, Brown, Kevin M, Gibbs, Richard, Trent, Jeffrey, Hayward, Nicholas K
Publicado 2011

POT1 loss-of-function variants predispose to familial melanoma

por Robles-Espinoza, Carla Daniela, Harland, Mark, Ramsay, Andrew J., Aoude, Lauren G., Quesada, Víctor, Ding, Zhihao, Pooley, Karen A., Pritchard, Antonia L., Tiffen, Jessamy C., Petljak, Mia, Palmer, Jane M., Symmons, Judith, Johansson, Peter, Stark, Mitchell S., Gartside, Michael G., Snowden, Helen, Montgomery, Grant W., Martin, Nicholas G., Liu, Jimmy Z., Choi, Jiyeon, Makowski, Matthew, Brown, Kevin M., Dunning, Alison M., Keane, Thomas M., López-Otín, Carlos, Gruis, Nelleke A., Hayward, Nicholas K., Bishop, D. Timothy, Newton-Bishop, Julia A., Adams, David J.
Publicado 2014